Neuroprotection and dopamine agonists

Neurology

Volumn 58, Issue 4 SUPPL. 1, 2002, Pages

  Schapira, Anthony H V ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Dopamine agonists; Free radicals; Mitochondria; Parkin; Parkinson's disease Synuclein; Pramipexole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE; PRAMIPEXOLE; PROTEOME; ROTENONE; NEUROPROTECTIVE AGENT;

ANTIOXIDANT ACTIVITY; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CELL FUNCTION; CELL MEMBRANE STEADY POTENTIAL; CLINICAL FEATURE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; DRUG RESEARCH; ENZYME ACTIVITY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MITOCHONDRIAL MEMBRANE; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; RODENT; SUBSTANTIA NIGRA; TWINS; ANIMAL; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0037176885     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.58.suppl_1.s9     Document Type: Review

References (110)

1. A family study of parkinsonism
2. Parkinson's disease. A genetic study
3. Parkinson's disease: A genetic study
4. Environmental antecedents of young-onset Parkinson's disease
5. Arteriosclerosis, hereditary, and some previous infections in the etiology of Parkinson's disease. A case-control study
6. Familial Parkinson's disease
7. Parkinson's disease: A test of the multifactorial etiologic hypothesis
8. Increased risk of Parkinson's disease in parents and siblings of patients
9. Familial Parkinson's disease: A clinical genetic analysis
10. Increased risk of Parkinson's disease in relatives of patients
11. Environmental and genetic risk factors in Parkinson's disease: A case control study in southern Italy
12. Risk of Parkinson's disease among first-degree relatives: A community-based study
13. A clinical genetic study of Parkinson's disease: Evidence for dominant transmission
14. Genetics of Parkinson's disease
15. Parkinson's disease in 65 pairs of twins and in a set of quadruplets
16. A case-control study of twin pairs discordant for Parkinson's disease: A search for environmental risk factors
17. Parkinson's disease in twins
18. Parkinson's disease in a nationwide twin cohort
19. Parkinson's disease in twins
20. Twin studies and the genetics of Parkinson's disease - A reappraisal
21. Epidemiology of Parkinson's disease
22. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy
23. The role of inheritance in sporadic Parkinson's disease: Evidence for a longitudinal study of dopaminergic function in twins
24. A large kindred with autosomal dominant Parkinson's disease
25. Clinical genetic analysis of Parkinson's disease in the Contursi kindred
26. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
27. Mutation in the α-synuclein gene identified in families with Parkinson's disease
28. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
29. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases
30. The role of alpha synuclein gene mutation in patients with sporadic Parkinson's disease in the UK
31. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease
32. Low frequency of α-synuclein mutations in familial Parkinson's disease
33. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
34. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal
35. The rat brain synucleins; family of proteins transiently associated with neuronal membrane
36. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
37. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early onset Parkinson's disease
38. Alpha-synuclein in Lewy bodies
39. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis
40. Cellular defences against unfolded proteins: A cell biologist thinks about neurodegenerative disease
41. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
42. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
43. Oxidative stress induces amyloid-like aggregate formation of NACP-alpha-synuclein in vitro
44. α-synuclein promotes mitochondrial deficit and oxidative stress
45. Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein
46. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity
47. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells
48. α-synuclein and Parkinson's disease: Selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo
49. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
50. A Drosophilia model of Parkinson's disease
51. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain
52. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27
53. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
54. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the parkin gene in affected individuals
55. Association between early-onset Parkinson's disease and mutations in the parkin gene
56. Familial juvenile parkinsonism: Clinical and pathological study in a family
57. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
58. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene
59. Localization of a novel locus for autosomal recessive early onset parkinsonism, PARK6, on human chromosome 1p35-p36
60. The ubiquitin pathway in Parkinson's disease
61. Glutathione peroxidase activity in Parkinson's disease
62. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains
63. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
64. Parkinson's disease: A disorder due to nigral glutathione deficiency
65. A selective increase in particulate superoxide dismutase activity in Parkinson's substantia nigra
66. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus
67. Superior dismutase and Parkinson's disease
68. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease
69. Lipid peroxidation as cause of nigral death in Parkinson's disease
70. Oxidative stress as a cause of Parkinson's disease
71. A marker of oxy-radical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain
72. Selective increase of iron in substantia nigra zona compacta in parkinsonian brains
73. Increased nigral iron content in post-mortem parkinsonian brain
74. Iron-melanin complex in substantia nigra of parkinsonian brains: An x-ray microanalysis
75. Iron-melanin complex in substantia nigra of parkinsonian brains: An x-ray microanalysis
76. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An x-ray microanalysis
77. Decreased ferritin levels in brain in Parkinson's disease
78. Complex I, iron and ferritin in Parkinson's disease substantia nigra
79. Mitochondrial complex I deficiency in Parkinson's disease
80. Titrating the effects of mitochondrial complex I impairment in the cell physiology
81. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia
82. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
83. Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration?
84. Inflammatory cytokines within the central nervous system: Sources, function, and mechanism of action
85. Cytokines and the nervous system I: Expression and recognition
86. Science, medicine, and the future: Parkinson's disease
87. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
88. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
89. Biochemical abnormalities and excitotoxicity in Huntington's disease brain
90. Mitochondrial implication in accidental and programmed cell death: Apoptosis and necrosis
91. Mitochondria as regulators of apoptosis: Doubt no more
92. Molecular characterization of mitochondrial apoptosis-inducing factor
93. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
94. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
95. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
96. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial
97. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase
98. 2 and 6-hydroxydopamine
99. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines
100. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro
101. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats
102. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
103. + toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential
104. Protective effects of the antiparkinsoniam drugs telipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-S75Y cells
105. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-χ Bax, Bak, Bad, ICH-I and CPP32, in Alzheimer's disease
106. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
107. Neuroprotection by pramipexole against dopamine and levodopa-induced cytotoxicity
108. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
109. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole